American Water Works Company Inc vs Sana Biotechnology Inc — how do they compare? American Water Works Company Inc trades at $131.69 (market cap $25.69B), while Sana Biotechnology Inc trades at $3.56 (market cap $1.02B). The key difference: American Water Works Company Inc is far larger — about 25.2× Sana Biotechnology Inc's market cap, and American Water Works Company Inc pays a 2.72% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| AWK | SANA | |
|---|---|---|
Market Cap | $25.69B | $1.02B |
Sector | Utilities | Health |
52-Week High | $147.00 | $5.92 |
52-Week Low | $121.13 | $2.68 |
Enterprise Value | $41.25B | $989.96M |
Dividend Yield | 2.72% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SANA Biotechnology trades at $3.64, down 5.45% over 24 hours, with a bullish technical signal from moving averages but neutral oscillators. The company reported a net loss of $244.17 million for 2025, with negative cash flow from operations of $143.83 million, though recent earnings have shown some beats against expectations. Analyst sentiment is strongly positive with 82% buy ratings, supported by recent clinical data presentations and strategic collaborations announced in 2026.
The outlook remains speculative given deep losses and high cash burn, but strong analyst backing and promising preclinical updates offer potential for long-term growth if clinical milestones are met. Key risks include ongoing operational losses, reliance on financing, and clinical trial outcomes.
Trailing returns across standard periods
Latest headlines on both assets
American Water Works is the largest investor-owned U.S. water and wastewater utility, serving approximately 3.5 million customers in 16 states. It provides water and wastewater services to residential, commercial, and industrial customers and operates predominantly in regulated markets. The company's only nonregulated business is water services for military bases, which operates under long-term contracts.
Read more on AWK →Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →